iDose-Enabled Glaucoma Franchise Inflection

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on the treatment of glaucoma, corneal disorders, and retinal disease. The company's commercial foundation is the iStent family of micro-invasive glaucoma surgery (MIGS) devices, which are implanted during cataract surgery to improve aqueous humor outflow and reduce intraocular pressure. These devices generate revenue on a per-procedure basis, sold to ophthalmic surgeons and ambulatory surgery centers, with reimbursement flowing through the cataract surgery payment bundle.

The growth engine is iDose TR, a sustained-release travoprost implant designed to deliver a continuous therapeutic dose of a prostaglandin analog directly into the eye over an extended period, replacing the daily eyedrop regimen that defines first-line glaucoma therapy. This shifts the company's revenue base from a surgical device model toward a drug-device combination model with different pricing, reimbursement, and commercial dynamics.

The customer base is highly concentrated among a relatively small number of high-volume cataract and glaucoma surgeons in the United States, with international expansion layered on top. Scale is modest in absolute revenue terms — roughly $560M on our FY2026 estimate — but the company addresses a glaucoma population that numbers in the tens of millions globally. The market cap of $9.5B on 58.98M shares reflects the market's expectation that the addressable opportunity is far larger than current revenue implies.

Near-term (FY2026–FY2027): The primary driver is iDose TR procedure volume and the pace at which surgeons adopt the implant into their existing cataract and standalone glaucoma workflows. Revenue growth in this window is dominated by U.S. adoption, with reimbursement clarity as the gating factor. Gross margin should expand as iDose TR mix rises, though operating expenses — particularly the sales force dedicated to a new procedural motion — will grow faster than revenue near-term, keeping EPS negative.

Medium-term (FY2028–FY2030): The second wave of growth comes from international expansion and from broadening the iDose label into additional patient segments. If the company demonstrates durable IOP control beyond the initial treatment interval, repeat dosing becomes a recurring revenue driver rather than a one-time procedure. This is the scenario in which operating leverage finally materializes and EPS crosses into positive territory. Our model has that inflection in FY2028, contingent on iDose TR penetration holding above our base-case trajectory.

The trajectory here is a classic medtech launch curve: revenue compounding at roughly 20% annually while gross margin grinds higher on product mix, but operating expenses growing nearly as fast because the iDose TR commercial infrastructure is being built ahead of the revenue it will eventually support. The reported EPS of $-3.27 is the clearest signal that the company is in investment mode. The single most important variable in the model is the rate at which SG&A growth decelerates relative to revenue — that crossover is what turns this from a cash-consuming story into a cash-generating one, and it is the assumption we scrutinize most closely.

The glaucoma treatment market spans topical pharmaceuticals (the largest segment, estimated at $2B+ globally), surgical devices including MIGS, and laser therapy. The MIGS device segment — where GKOS built its franchise — has become crowded, with several competitors entering over the past decade and compressing the differentiation of first-generation stents. The sustained-release pharmaceutical segment is earlier and less contested, which is precisely why iDose TR carries the valuation weight it does.

Competitive positioning: GKOS retains a first-mover advantage in MIGS with the deepest surgeon relationships and the largest installed base of implanted devices, but that advantage is eroding as competitors match device performance. In sustained-release glaucoma therapy, the competitive set is thinner, and the company's clinical data package is a genuine differentiator — though not an unassailable one.

Named comparables:

Our DCF assumes revenue reaching roughly $1.1B by FY2031, gross margin expanding to the mid-80s on iDose TR mix, and operating margin crossing into positive territory in FY2028 with steady expansion thereafter. We apply a weighted average cost of capital in the 9–10% range — supported by the low beta of 0.77 but adjusted upward for the company's negative earnings and single-product concentration — and a terminal growth rate of 3.5%. That produces an enterprise value that, after adjusting for net cash, implies roughly $150–$165 per share. The sensitivity to the terminal growth rate is high: a 1-point change in terminal growth moves the per-share value by approximately $20.

Comparable-company multiples:

GKOS trades at a substantial premium to every comparable on revenue, which is only justifiable if iDose TR sustains a growth rate and margin profile that none of the peers possess. Our DCF and comparable work bracket the current price of $160.59, which is why we land at Hold rather than Buy or Sell.

• iDose TR adoption slower than modeled. The multiple embeds a steep penetration curve. Any deceleration in surgeon adoption or reimbursement friction would compress the revenue multiple sharply given the negative EPS base.
• Reimbursement and pricing pressure. As a drug-device combination product, iDose TR is exposed to payer scrutiny. Adverse coverage decisions or rate cuts would directly hit both revenue and gross margin.
• Competitive erosion in MIGS. The legacy iStent franchise faces a crowded field of MIGS devices. Share loss here would remove the revenue floor that currently supports the investment in iDose TR.
• Capital structure and dilution. With negative EPS and heavy commercial spend, the company may need to raise capital. A dilutive equity raise at a lower share price would compound the EPS problem for existing holders.
• Elevated short interest and volatility. At 8.55% of float shorted against a 162% 52-week trading range, the stock is prone to sharp moves in both directions on modest news flow, independent of fundamental developments.